Synthesis of Unsymmetrical Diarylureas via Pd-Catalyzed C–N Cross-Coupling Reactions by Breitler, Simon, Oldenhuis, Nathan J., Fors, Brett P., Buchwald, Stephen Leffler

Get full text
Get full text

Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL by Anne Rogiers, Laurence Willemot, Laura McDonald, Hilde Van Campenhout, Guy Berchem, Celine Jacobs, Nathalie Blockx, Andrée Rorive, Bart Neyns

Get full text

Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma by Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, McEwan P, Yuan Y, Juarez-Garcia A, Tyas D, Pritchard C

“…Eddie J Gibson,1 Najida Begum,1 Ian Koblbauer,1 George Dranitsaris,2 Danny Liew,3 Phil McEwan,4 Yong Yuan,5 Ariadna Juarez-Garcia,6 David Tyas,6 Clive Pritchard1 1Wickenstones Ltd, Abingdon, UK; 2Augmentium Pharma Consulting Inc., Toronto, ON, Canada; 3School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; 4Health Economics and Outcomes Research Ltd, Cardiff, UK; 5Bristol-Myers Squibb, Lawrenceville, NJ, USA; 6Bristol-Myers Squibb, Uxbridge, UKCorrespondence: Clive PritchardWickenstones Ltd., Units 24-26, 127 Olympic Avenue, Milton Park, Abingdon, Oxfordshire OX14 4SA, UKTel + 441865 959735Email Clive@wickenstones.comBackground: Existing economic model frameworks may not adequately capture the atypical treatment response patterns in immuno-oncology (I-O) compared with conventional therapies and thus may fail to represent the full clinical value associated with disease dynamics and improved survival.Objective: A cost-effectiveness analysis (CEA) of the I-O Regimen (nivolumab/ipilimumab) versus ipilimumab alone in advanced melanoma was carried out by applying a 5-state partitioned survival model (PSM) as a case study, to explore the I-O treatment response and clinical outcomes. …”
Get full text

Filarial nematode phenotypic screening cascade to identify compounds with anti-parasitic activity for drug discovery optimization by Natalie Hawryluk, Li Zhiru, Clotilde Carlow, Suzanne Gokool, Simon Townson, Tamara Kreiss, Agnieszka Chojnowski, Monika Prorok, John Siekierka, Alexandra Ehrens, Marianne Koschel, Nathaly Lhermitte-Vallarino, Coralie Martin, Achim Hoerauf, Geraldine Hernandez, Stacie Canan, Vikram Khetani, Jerome Zeldis, Sabine Specht, Marc P. Hübner, Ivan Scandale

Get full text

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy by Giuseppe Procopio, Prabhu Bhagavatheeswaran, Bernard Escudier, Chung-Han Lee, Shruti Shally Saggi, Suresh Nair, Ruth Perets, Michael A Carducci, Vincent Castonguay, Edmund Folefac, Sebastien J. Hotte, Wilson H Miller, Heshani Desilva

Get full text

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study by Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, Lionel D Lewis, Todd M Bauer, David F McDermott, Michael Carducci, Christian Kollmannsberger, Brian I Rini, Daniel Y C Heng, Jennifer Knox, Martin H Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J Hammers

Get full text

Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily Practice by Fernando Ramos, María Lourdes Hermosín, Marta Fuertes-Núñez, Pilar Martínez, Carlos Rodriguez-Medina, Manuel Barrios, Francisco Ibáñez, Teresa Bernal, Maria Teresa Olave, Miguel Ángel Álvarez, María Vahí, Teresa Caballero-Velázquez, Bernardo González, Albert Altés, Lorena García, Pascual Fernández, María Antonia Durán, Rocío López, Montserrat Rafel, Josefina Serrano

Get full text

Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement by Apostolia M. Tsimberidou, Laura A. Levit, Richard L. Schilsky, Steven D. Averbuch, Daniel Chen, John M. Kirkwood, Lisa M. McShane, Elad Sharon, Kathryn F. Mileham, Michael A. Postow

Get full text

Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma by Keri Toner, Carl E. Allen, Shweta Jain, Brad Kahl, John Leonard, Heather Wasserstrom, Jonathan W. Friedberg, Nita L. Seibel, Kara Kelly

Get full text

The relationship between Intensive Care Unit Length of Stay information and its operational performance by Esmaeil Bahalkeh, Imran Hasan, Yuehwern Yih

Get full text

An overview of the BOIN design and its current extensions for novel early-phase oncology trials by Revathi Ananthakrishnan, Ruitao Lin, Chunsheng He, Yanping Chen, Daniel Li, Michael LaValley

Get full text

Predicting analysis times in randomized clinical trials with cancer immunotherapy by Tai-Tsang Chen

Get full text

B07 HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS by R. Wester, M. van Duin, K.H. Lam, S.S. Couto, Y. Ren, M. Wang, T. Cupedo, B. van der Holt, H.B. Beverloo, A.L. Nigg, A. Thakurta, A.A. Waage, S. Zweegman, A. Broijl, P. Sonneveld

Get full text

Study of social disparities in pediatric laparoscopic appendectomy outcomes and cost by Sathyaprasad Burjonrappa

Get full text

Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial by John H Alexander, Christopher B Granger, Sigrun Halvorsen, Stephan Windecker, Dragos Vinereanu, Daniel M Wojdyla, Roxana Mehran, Shaun Goodman, Renato Lopes, Robert C. Welsh, Payam Dehghani, Ronald Aronson, Amit N Vora, Alexander Parkhomenko

Get full text

Фармакоэкономические аспекты применения статинов при краткосрочной гиполипидемической терапии

“…Сравнивались препараты симвастатина – Зокор (Merck Sharp & Dohme Idea, Inc., Швейцария) и Вазилип (KRKA, Словения), ловастатина – Мевакор (Merck Sharp & Dohme Idea, Inc., Швейцария) и Холетар (KRKA, Словения) и правастатина – Липостат (Bristol-Myers Squibb, США). После 1 мес. гиполипидемической диеты 50 пациентов с гиперлипидемией были рандомизированы на 5 групп по 10 человек. …”
Get full text

1378 Discovery and characterization of PM-4321, a selective inhibitor of the aryl hydrocarbon receptor (AHR) with anti-tumor immunomodulatory effects by Charles Sinclair, Luisa Salter-Cid, Benjamin Carter, Ming Bai, Christopher Wrocklage, Kritika Ramani, Anna Nicole Bosco, Iulian Pruteanu-Malinici, Lizeth Perales, Wojciech Dworakowski, Brenda K Eustace, Kun Don Yi, Seema Kumar, Matthew Abbinanti, Alessandra Bartolozzi, John Robert Proudfoot, Timothy Briggs, John Steven Taylor, Sheila Ranganath

Viral Infections and Autoimmune Disease: Roles of LCMV in Delineating Mechanisms of Immune Tolerance by Georgia Fousteri, Amy Dave Jhatakia

Get full text

A Single Phosphine Ligand Allows Palladium-Catalyzed Intermolecular C-O Bond Formation with Secondary and Primary Alcohols by Wu, Xiaoxing, Fors, Brett P., Buchwald, Stephen Leffler

Get full text
Get full text

First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2 by Ian M. Catlett, Urvi Aras, Lars Hansen, Yali Liu, Di Bei, Ihab G. Girgis, Bindu Murthy

Get full text